SUMMARY: Pseudomonas luteola has rarely been reported as a human pathogen. The clinical manifestations of P. luteola bacteremia and its susceptibility to antibiotics have not been characterized. This retrospective study was conducted at a 382-bed tertiary care center in Turkey. During the 9-year study period, 7 patients (5 females and 2 males) were diagnosed with P. luteola bacteremia. Six of these patients had hospital-acquired bacteremia, whereas 1 patient had community-acquired P. luteola infection. All patients had monomicrobial bacteremia. Antimicrobial susceptibility testing revealed that all strains of P. luteola were sensitive to amikacin, gentamicin, trimethoprim-sulfamethoxazole, and meropenem, and that all strains were resistant to piperacillin-tazobactam, aztreonam, and colistin. In conclusion, we believe that P. luteola can cause both community-and hospital-acquired bacteremia. Amikacin, gentamicin, trimethoprim-sulfamethoxazole, and meropenem were effective against P. luteola in the present study.
INTRODUCTION
Pseudomonas luteola, which is also called Chryseomonas luteola, is a nonfermenting gram-negative bacterium that was previously classified in US Centers for Disease Control and Prevention group Ve-1. P. luteola is rarely reported as human pathogen, and the literature includes only a few cases of infection by this bacterium (1, 2) . The present study aimed to determine the clinical characteristics, antibiotic susceptibility, treatment regimens, and outcomes in 7 pediatric patients with P. luteola bacteremia.
MATERIALS AND METHODS
This study was conducted at Dr. Sami Ulus Maternity and Children's Health and Diseases Research and Education Hospital, a 382-bed tertiary care center in Ankara, Turkey. The study included patients aged 1 month-18 years who developed P. luteola bacteremia between January 2005 and November 2013. The patients' medical records were reviewed. The following variables were analyzed patients' age and gender, primary diagnosis, peripheral blood leukocyte count and serum C-reactive protein (CRP) level at the time blood culture was obtained, use of total parenteral nutrition, central vascular access and mechanical ventilation for ＞48 h, duration of hospitalization prior to bacteremia, number of positive blood cultures, antimicrobial susceptibility profile, empirical antibiotic regimen, alteration of antibiotic treatment because of clinical deterioration or antibiogram results, duration of antibiotic treatment, and treatment outcome.
P. luteola bacteremia was diagnosed based on the isolation of bacterium in 1 peripheral blood cultures. Bacteremia was considered hospital-acquired if it occurred 48 h after hospital admission. Communityacquired infection was defined as bacteremia that occurred within the first 48 h after hospital admission without exposure to a healthcare facility. Bacterial growth was detected in blood cultures using a BacT/Alert  3D automated system (bioM Áerieux, Marcy l'Etoile, France). The organism with slow growth and the presence of small yellow-orange colonies on eosin methylene blue agar and blood agar after 48 h incubation were considered in the identification process. It was identified as catalase-positive and oxidase-negative in standard biochemical tests. It utilized glucose, mannitol, and maltose oxidatively; hydrolyzed esculin; and reduced nitrates to nitrites. It did not decarboxylate lysine, did not hydrolyze urea, and did not produce indoles. Identification of P. luteola was performed using the Vitek 2 (bioMerieux) automated system. The susceptibility of bacterial isolates to antimicrobial agents was initially determined via the routine disk diffusion method, according to the guidelines of the Clinical and Laboratory Standards Institute's guideline for other non-Enterobacteriaceae (3). Bacterial isolates were tested using the following antimicrobials: amikacin; gentamicin; aztreonam; ceftriaxone; ceftazidime; cefoperazone-sulbactam; ciprofloxacin; imipenem; piperacillin; piperacillin-tazobactam; and trimethoprim-sulfamethoxazole. Statistical analysis was performed using SPSS v.15.0 for Windows (SPSS, Inc., Chicago, IL, USA).
RESULTS
During the 9-year study period, 7 patients (5 females and 2 males) were diagnosed with P. luteola bacteremia. 
PI, piperacillin; AZT, aztreonam; SXT, trimethoprim-sulfamethoxazole; CP, ciprofloxacin; GM, gentamicin; CPZ, cephoperazon-sulbactam; N, not performed; R, resistant; S, susceptible.
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The mean age of the patients was 44 ± 40.8 months (median: 24 months; range: 11-105 months). All patients were febrile when blood was obtained for culture. Two patients had a central vascular catheter at the time of bacteremia, and 1 patient was receiving mechanical ventilation before P. luteola bacteremia developed. Three patients (42.8z) had leukocytosis (＞15,000 leukocytes/mL), and 5 patients (71.4z) had an elevated CRP level (＞10 mg/dL) at the time of obtain blood culture. All patients had monomicrobial bacteremia, as there were no cases of concomitant microorganism infection. The clinical characteristics of 7 patients with P. luteola bacteremia are shown in Table 1 . Six patients had hospital-acquired bacteremia, with a median interval from hospitalization to the development of bacteremia of 13 days, whereas 1 patient had community-acquired P. luteola infection; she had protein-losing enteropathy and presented with a fever of 38.39 C, vomiting, and diarrhea. Initial empirical therapies and alterations to the treatment regimens based on the results of drug susceptibility testing of P. luteola isolates are presented in Table 2 .
Recurrent P. luteola bacteremia occurred in 1 patient (case no. 4). Although this patient was being followedup in the hospital for a diagnosis of Miller-Dieker syndrome, fever and respiratory distress developed, and respiratory support with mechanical ventilation was required. His CRP level and leukocyte count were extremely elevated, and chest radiography revealed bilateral infiltration. Colistin was added to the initial antibiotic treatment following a diagnosis of nosocomial pneumonia. P. luteola was cultured in blood that was obtained at the beginning of the patient's febrile period. After 48 h, P. luteola was again isolated in the second blood culture while the patient was receiving colistin treatment. As colistin-resistant P. luteola was identified in both blood cultures, colistin was withdrawn, and the patient was treated with imipenem. Antimicrobial susceptibility testing illustrated that all strains of P. luteola were sensitive to amikacin, gentamicin, trimethoprim-sulfamethoxazole, and meropenem and resistant to piperacillin-tazobactam, aztreonam, and colistin. In total, 15 and 85z of the isolates were resistant to ciprofloxacin and ceftazidime, respectively. Antimicrobial susceptibility test results of all 7 identified strains are presented in Table 3 .
The duration of antibiotic treatment based on antibiograms of P. luteola was 19 ± 9.3 days. In all, 6 patients recovered, whereas 1 patient with congenital hypophosphatasia and severe malnutrition who developed P. luteola bacteremia on the 126th day of hospitalization died. Although this patient was treated with effective antibiotic against to P. luteola and mechanical ventilation, the patient died 24 days after a positive blood culture.
DISCUSSION
P. luteola is a member of the nonflorescent group of the family Pseudomonadaceae. It is a catalase-positive, oxidase-negative, motile gram-negative bacillus that forms yellow-pigmented colonies in blood cultured on MacConkey agar. P. luteola is an environmental organism that is also found in healthcare environments (1, 2) . P. luteola rarely causes community-or hospitalacquired infection in humans, and the literature includes only few case reports. In a study from Tanzania that investigated extended spectrum beta-lactamases among gram-negative bacteria of nosocomial origin, P. luteola was reported as a nosocomial pathogen in 1 patient in an intensive care unit of a tertiary hospital (4) . In this study, we reviewed all cases of infection related to P. luteola from 1988 to date (Table 4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Of the reported cases of P. luteola, bacteremia was the most common infection. Community-acquired infections were more commonly reported than hospital-acquired infections. Only 6 pediatric patients with P. luteola infection have been reported. P. luteola infections have been reported from the United States of America, Europe, Africa, and Western and Southern Asia . Considering the reports, it appears that P. luteola infections are rarely seen in pediatric patients, and that they are more often community-acquired and cause a variety of infections. Consistent with the aforementioned studies, P. luteola was observed to cause community-and hospital-acquired infections, but our study indicated that P. luteola caused bacteremia mainly in the hospital care setting. Further reports are required to verify this ovservation. P. luteola infections are extremely rare in the pediatric age group. Because our center is a children's hospital, all of our patients were in the pediatric age group.
It has been reported that P. luteola can infect critically ill patients who have undergone surgery and/or implantation with indwelling devices (8) . Among the present study's patients who had hospital-acquired P. luteola infection, underlying chronic disease, a long duration of hospitalization, the presence of a central vascular catheter, the administration of total parenteral nutrition, and mechanical ventilation-all well-known risk factors for hospital-acquired infections-might have predisposed them to P. luteola infection.
There is no standardized or recommended antimicrobial regimen for P. luteola infections. In the present study, antibiotic susceptibility testing revealed that amikacin, gentamicin, trimethoprim-sulfamethoxazole, and meropenem had potent activity against P. luteola isolates. Most strains were resistant to some of the antipseudomonal antibiotics. It was reported that P. luteola isolates were susceptible to imipenem, ciprofloxacin, and ceftazidime. To the best of our knowledge, there are no published data indicating that P. luteola is susceptible to colistin. In the present study, P. luteola isolates were highly resistant to colistin in vitro, and empirical colistin treatment failed in 1 patient. It was reported that monotherapy was sufficient in most cases (5, 9, 17, 20) . We believe that carbapenems might be suitable for hospital-acquired P. luteola infections, as all of the isolates studied were susceptible to imipenem.
Among the cases of P. luteola infection reported in the literature, 4 patients died (8, 17, 19) . In the present study, only 1 patient with underlying congenital hypophosphatasia died, whereas all of the other patients recovered following an uncomplicated course.
The limitation of our study is that the identification of the P. luteola isolates could not be confirmed by genetic analysis, as a facility for this analysis is not available at our institution. The diagnostic sensitivities and specificities of these tests for the investigation of most positive blood cultures are extremely high, but some PCR assays could fail to identify gram-negative rods including P. luteola and no specific PCR assay for P. luteola had been developed (25) .
In conclusion, we believe that P. luteola may be more common in children than previously reported. P. luteola can cause both community-and hospital-acquired bacteremia. Amikacin, gentamicin, trimethoprim-sulfamethoxazole, and meropenem were effective against P. luteola in the present study. Empirical treatment of nosocomial infections, including P. luteola infections, with carbapenem antibiotics is considered the appropriate regimen at our hospital.
